LYNPARZA (olaparib)

LynparzaTM (olaparib) is a first‐in‐class PARP inhibitor (PARPi) that allows women with BRCA mutated (BRCAm) platinum‐sensitive relapsed high-grade serous ovarian cancer to extend progression‐free survival (PFS).1-3

Prescribing Information

Indications and Usage

LynparzaTM (olaparib) is indicated as monotherapy for the maintenance treatment of adult patients with platinum-sensitive relapsed BRCAm high-grade serous ovarian cancer (including fallopian tube or primary peritoneal) who are in response (complete response or partial response) to platinum-based chemotherapy.4

Lynparza is recommended by NICE within its marketing authorisation for patients only if:

  • They have had 3 or more courses of platinum based chemotherapy and
  • The drug cost of Lynparza for people who remain on treatment after 15 months will be met by AstraZeneca.5

Lynparza is recommended by the SMC in line with its marketing authorisation.6